Celsion Corporation Stock Nasdaq
Equities
US15117N3052
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 13.26M 18.13M |
---|---|---|---|---|---|
Net income 2024 * | -21M -28.72M | Net income 2025 * | -25M -34.19M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.67
x | P/E ratio 2025 * |
-0.86
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.85% |
Latest transcript on Celsion Corporation
Managers | Title | Age | Since |
---|---|---|---|
Stacy Lindborg
CEO | Chief Executive Officer | 53 | 21-06-03 |
Michael Tardugno
CHM | Chairman | 73 | 07-01-02 |
Sebastien Hazard
CTO | Chief Tech/Sci/R&D Officer | 53 | 12-10 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 56 | 21-06-07 | |
Frederick Fritz
BRD | Director/Board Member | 73 | 11-07-07 |
James Dentzer
BRD | Director/Board Member | 57 | 22-09-02 |
1st Jan change | Capi. | |
---|---|---|
+20.17% | 127B | |
+24.67% | 117B | |
+25.44% | 27.67B | |
-17.74% | 20.33B | |
-15.17% | 16.79B | |
-15.21% | 15.63B | |
+11.91% | 14.84B | |
-47.10% | 14.65B | |
+54.50% | 14.43B |